The nation of Zimbabwe has turned down a significant US healthcare agreement valued at $367m (272 million pounds) over five years due to Washington's insistence on sensitive data.
This move was revealed after a government memo from December was leaked, indicating that Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
An official spokesperson has since clarified that the United States was requesting genetic material for scientific study and profit but refused to share the benefits from any future treatments.
"We must now begin the challenging and unfortunate task of scaling back our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had furnished over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has appealed for continued talks to reach a agreement acceptable to all parties so the nation's vital HIV programme can be sustained.
Broader Implications
This development follows a similar situation in neighbouring Kenya, where a court halted a related health funding agreement after concerns were raised about the safety of citizens' medical information.
Since returning to office recently, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
USAID had managed assistance for the American government, but Trump claimed its expenditure was "inefficient" and his administration was seeking direct bilateral agreements to enhance transparency and responsibility.
According to statements, 16 African countries have to date signed these new health pacts, constituting more than $18.3bn in new funding.
Details of the Declined Deal
The funds for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration could have provided immense advantages for Zimbabwean communities, particularly the 1.2 million currently receiving HIV treatment through US-supported programmes," Tremont commented.
However, government spokesperson Nick Mangwana said the proposed deal was "unequal".
"Zimbabwe was being asked to surrender its genetic material and health information over an extended period, with no corresponding assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that could result from that shared data," his statement read.
"Effectively, our nation would provide the basic resources for scientific discovery with no assurance that the resulting innovations would be accessible to our people should a new disease outbreak arise."
Sovereignty and Global Health
He also said that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were upending systems previously set up through the global organization.
Mangwana cited its Pandemic Benefit-Sharing scheme designed to manage future global health emergencies.
"This framework is designed to ensure that when a nation provides its data, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised solely by those with the resources to create them."
These objections over the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We welcome continued dialogue with our US partners on how subsequent co-operation could be arranged in a way that honours the sovereignty and interests of both nations."
Medical Community Response
Medical experts expressed it acknowledged the official position, but urged that negotiations should continue given that a large portion of the country's HIV programmes relied on international support.
"Where technical issues exist, including those involving information security or implementation frameworks, these can often be resolved via detailed discussion and mutually agreed protections," the group said.
The halted deal highlights the continuing tensions between accepting crucial international aid and safeguarding local interests in an increasingly data-driven world.